Dioscure Therapeutics
Research - Bonn, North Rhine-Westphalia, Germany
Dioscure Therapeutics Employees
Dioscure Therapeutics Details
DiosCURE is developing next-generation immunotherapies focused on a novel approach against SARS-CoV-2. The Company's proprietary bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergistic combinations of single-domain antibodies, constructed following structural information and optimized for potency as well as their potential to avoid the emergence of escape mutants. DiosCURE designed lead candidates that target two different epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated and manufactured at a large-scale standardized process.
Dioscure Therapeutics Technologies
Email Providers
Outlook
CMS
Wix
Tag Management
Google Tag Manager
Social Login
Facebook Login (Connect)
Hosting
Google Cloud Hosting
Other
Mobile Friendly